MX362614B - Sistema de liberación transdérmico. - Google Patents
Sistema de liberación transdérmico.Info
- Publication number
- MX362614B MX362614B MX2015016123A MX2015016123A MX362614B MX 362614 B MX362614 B MX 362614B MX 2015016123 A MX2015016123 A MX 2015016123A MX 2015016123 A MX2015016123 A MX 2015016123A MX 362614 B MX362614 B MX 362614B
- Authority
- MX
- Mexico
- Prior art keywords
- buprenorphine
- sensitive adhesive
- adhesive layer
- pressure
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive plasters or dressings
- A61F13/0246—Adhesive plasters or dressings characterised by the skin adhering layer
- A61F13/0256—Adhesive plasters or dressings characterised by the skin adhering layer characterized by the parametric properties of the adhesive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Abstract
La invención se relaciona con sistema terapéutico transdérmico para la administración transdérmica de buprenorfina, comprendiendo una estructura de capa auto-adhesiva conteniendo buprenorfina comprendiendo A) una capa de respaldo impermeable a la buprenorfina, y B) una capa adhesiva sensible a la presión conteniendo buprenorfina sobre dicha capa de respaldo impermeable a la buprenorfina, la capa adhesiva comprendiendo a) al menos un adhesivo sensible a la presión de base polimérica, b) una cantidad efectiva analgésicamente de base de buprenorfina o una sal farmacéuticamente aceptable de la misma, c) una sustancia que aumenta la viscosidad en una cantidad de alrededor de 0,1% a alrededor de 8% de dicha capa adhesiva sensible a la presión conteniendo buprenorfina, y d) un ácido carboxílico seleccionado del grupo consistente de ácido oleico, ácido linoleico, ácido linolénico, ácido levulínico y mezclas de los mismos, en una cantidad suficiente para que dicha cantidad efectiva analgésicamente de buprenorfina sea solubilizada en él para formar una mezcla incluyendo dicha sustancia que aumenta la viscosidad , y donde la mezcla conteniendo ácido carboxílico-, buprenorfina- y sustancia que aumenta la viscosidad forma depósitos dispersos en dicho adhesivo sensible a la presión, y donde dicha capa adhesiva sensible a la presión conteniendo buprenorfina es la capa en contacto con la piel.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361830975P | 2013-06-04 | 2013-06-04 | |
PCT/EP2014/061567 WO2014195352A1 (en) | 2013-06-04 | 2014-06-04 | Transdermal delivery system |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015016123A MX2015016123A (es) | 2016-07-21 |
MX362614B true MX362614B (es) | 2019-01-28 |
Family
ID=51022809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015016123A MX362614B (es) | 2013-06-04 | 2014-06-04 | Sistema de liberación transdérmico. |
Country Status (34)
Country | Link |
---|---|
US (6) | US20160008294A1 (es) |
EP (2) | EP3106153A1 (es) |
JP (1) | JP6559121B2 (es) |
KR (1) | KR102302505B1 (es) |
CN (1) | CN105377245B (es) |
AP (1) | AP2015008920A0 (es) |
AR (1) | AR096521A1 (es) |
AU (1) | AU2014276910B2 (es) |
BR (1) | BR112015029920A2 (es) |
CA (1) | CA2914425C (es) |
CL (1) | CL2015003377A1 (es) |
CR (1) | CR20150647A (es) |
CY (1) | CY1118054T1 (es) |
DE (1) | DE112014002664T5 (es) |
DK (1) | DK2810646T3 (es) |
EA (1) | EA201592246A1 (es) |
ES (1) | ES2599802T3 (es) |
GB (1) | GB2529789A (es) |
HK (2) | HK1204766A1 (es) |
HU (1) | HUE031662T2 (es) |
LT (1) | LT2810646T (es) |
MA (1) | MA38698B1 (es) |
MX (1) | MX362614B (es) |
NI (1) | NI201500170A (es) |
PE (1) | PE20160002A1 (es) |
PH (1) | PH12015502550A1 (es) |
PL (1) | PL2810646T3 (es) |
PT (1) | PT2810646T (es) |
SG (1) | SG11201509218SA (es) |
SI (1) | SI2810646T1 (es) |
TN (1) | TN2015000493A1 (es) |
TW (1) | TW201509416A (es) |
WO (1) | WO2014195352A1 (es) |
ZA (1) | ZA201509309B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006054731B4 (de) | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie |
CN104114161A (zh) | 2011-12-12 | 2014-10-22 | Lts勒曼治疗系统股份公司 | 包含丁丙诺啡的经皮递送系统 |
TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片 |
WO2014195352A1 (en) | 2013-06-04 | 2014-12-11 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system |
BR112015032929B1 (pt) | 2013-07-03 | 2022-08-23 | Lts Lohmann Therapie-Systeme Ag | Sistema terapêutico transdérmico com componente eletrônico e métodos de produção de um sistema terapêutico transdérmico |
US11752110B2 (en) | 2014-05-20 | 2023-09-12 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
CN106456566B (zh) | 2014-05-20 | 2020-06-16 | Lts勒曼治疗系统股份公司 | 含罗替戈汀的经皮递送系统 |
CN106456567A (zh) | 2014-05-20 | 2017-02-22 | Lts勒曼治疗系统股份公司 | 在经皮递送系统中调节活性剂释放的方法 |
US10406152B2 (en) | 2015-03-10 | 2019-09-10 | Rhodes Technologies | Acetate salt of buprenorphine and methods for preparing buprenorphine |
US20180256562A1 (en) * | 2015-09-14 | 2018-09-13 | Amneal Pharmaceuticals Llc | Transdermal Delivery System |
AR102214A1 (es) * | 2015-10-08 | 2017-02-15 | Amarin Tech S A | Un dispositivo para la administración transdermal de buprenorfina |
US10486690B2 (en) * | 2016-12-14 | 2019-11-26 | Bendix Commerical Vehicle Systems, Llc | Front end motor-generator system and hybrid electric vehicle operating method |
MX2019007391A (es) | 2016-12-20 | 2019-08-16 | Lts Lohmann Therapie Systeme Ag | Sistema terapeutico transdermico que contiene asenapina. |
CN110087641B (zh) | 2016-12-20 | 2024-03-12 | 罗曼治疗系统股份公司 | 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统 |
US20180221297A1 (en) * | 2017-02-03 | 2018-08-09 | Kirti H. Valia | System and Method for Improving Adhesion of Transdermal Delivery Devices |
CN110799180A (zh) | 2017-06-26 | 2020-02-14 | 罗曼治疗系统股份公司 | 含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统 |
BR112020003314A2 (pt) * | 2017-09-04 | 2020-08-25 | Lts Lohmann Therapie-Systeme Ag | sistema de liberação transdérmico incluindo um emulsificante |
WO2019064026A1 (en) | 2017-09-29 | 2019-04-04 | Orexo Ab | NEW PHARMACEUTICAL COMPOSITIONS |
WO2019166572A1 (en) | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
US20210000755A1 (en) | 2018-03-13 | 2021-01-07 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system for the transdermal administration of buprenorphine comprising a silicone acrylic hybrid polymer |
AU2019261403A1 (en) * | 2018-04-25 | 2020-11-12 | Shinkei Therapeutics, Inc. | Tetrabenazine transdermal delivery device |
WO2019243452A1 (en) | 2018-06-20 | 2019-12-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
GB201904767D0 (en) | 2019-04-04 | 2019-05-22 | Orexo Ab | New pharmaceutical compositions |
CN113952319A (zh) * | 2021-11-30 | 2022-01-21 | 烟台大学 | 一种含丁丙诺啡的骨架型透皮贴剂及其制备方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1136214A (en) | 1965-06-15 | 1968-12-11 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
US3474101A (en) | 1960-09-05 | 1969-10-21 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
US4588580B2 (en) | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
CA2002299A1 (en) | 1988-11-10 | 1990-05-10 | Eugene G. Drust | Compositions for the transdermal delivery of buprenorphine salts |
US5788983A (en) | 1989-04-03 | 1998-08-04 | Rutgers, The State University Of New Jersey | Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes |
DE3939376C1 (es) | 1989-11-29 | 1991-05-08 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De | |
US5240711A (en) | 1989-11-29 | 1993-08-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system comprising as active component buprenorphine |
US5069909A (en) | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
DE4446600A1 (de) | 1994-12-24 | 1996-06-27 | Lohmann Therapie Syst Lts | Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen |
US6365178B1 (en) * | 1996-09-06 | 2002-04-02 | Watson Pharmaceuticals, Inc. | Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
DE19738855C2 (de) * | 1997-09-05 | 2001-01-04 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht |
DE19922662C1 (de) | 1999-05-18 | 2000-12-28 | Sanol Arznei Schwarz Gmbh | Transdermales therapeutisches System (TTS) Tolterodin enthaltend |
DE19958554C2 (de) | 1999-07-02 | 2002-06-13 | Lohmann Therapie Syst Lts | Mikroreservoirsystem auf Basis von Polysiloxanen und ambiphilen Lösemitteln und ihre Herstellung |
HU229085B1 (en) * | 1999-07-02 | 2013-07-29 | Lohmann Therapie Syst Lts | Microreservoir system on the basis of polysiloxanes and ambiphilic solvents |
CN1423559A (zh) | 2000-02-08 | 2003-06-11 | 欧罗赛铁克股份有限公司 | 包含阿片样激动剂和拮抗剂的控释组合物 |
US6682757B1 (en) | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
WO2002083135A2 (en) | 2001-02-16 | 2002-10-24 | Grünenthal GmbH | Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence |
DE10141651B4 (de) | 2001-08-24 | 2007-02-15 | Lts Lohmann Therapie-Systeme Ag | Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung |
AU2002350207A1 (en) | 2001-11-19 | 2003-06-10 | Control Delivery Systems, Inc. | Topical delivery of codrugs |
US20050118245A1 (en) | 2002-03-27 | 2005-06-02 | Wilsmann Klaus M. | Assembled unit consisting of individually separable, transdermal, therapeutic systems |
DE10213772A1 (de) | 2002-03-27 | 2003-10-09 | Gruenenthal Gmbh | Zusammenhängende Einheit aus vereinzelbaren transdermalen therapeutischen Systemen |
US20050191340A1 (en) | 2002-08-09 | 2005-09-01 | Gruenenthal Gmbh | Opioid-receptor antagonists in transdermal systems having buprenorphine |
DK1526848T3 (da) | 2002-08-09 | 2007-10-22 | Gruenenthal Gmbh | Opiod-receptorantagonister i transdermale systemer med buprenorphin |
SI1572167T1 (sl) | 2002-12-13 | 2008-12-31 | Euro Celtique Sa | Transdermalni buprenorfinski dozirni reĹľim za analgezijo |
RU2324372C2 (ru) | 2003-03-25 | 2008-05-20 | Моринда, Инк. | Селективное ингибирование продукции эстрогена и обеспечение эстрогенного действия в организме человека |
PL219512B1 (pl) * | 2003-04-14 | 2015-05-29 | Lohmann Therapie Syst Lts | Plaster miejscowy, zastosowanie plastra miejscowego i sposób wytwarzania plastra miejscowego |
US8790689B2 (en) | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
US7182955B2 (en) | 2003-04-30 | 2007-02-27 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
US8007737B2 (en) * | 2004-04-14 | 2011-08-30 | Wyeth | Use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices |
DE102004019916A1 (de) * | 2004-04-21 | 2005-11-17 | Grünenthal GmbH | Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster |
DE102004045599A1 (de) | 2004-09-17 | 2006-03-23 | Grünenthal GmbH | System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen |
DE102004062647A1 (de) | 2004-12-21 | 2006-06-29 | Kronotec Ag | Holzfaserdämmstoffplatte bzw.- matte |
DE102004062614B4 (de) | 2004-12-24 | 2011-12-29 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit aktivierbarer Übersättigung und kontrollierter Permeationförderung sowie Verfahren zu dessen Herstellung |
DE102006026578B4 (de) | 2006-06-08 | 2009-01-08 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffpartikelhaltiges Transdermales Therapeutisches System mit erhöhtem Wirkstofffluss und Verfahren zu seiner Herstellung sowie Verwendung |
DE102006054731B4 (de) * | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie |
DE102006054732B4 (de) | 2006-11-21 | 2010-12-30 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren |
JP5235384B2 (ja) | 2007-11-08 | 2013-07-10 | リンテック株式会社 | 貼付シート |
GB0815435D0 (en) | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
EP2366388A1 (de) * | 2010-03-17 | 2011-09-21 | Ratiopharm GmbH | Nicht-okklusives transdermales therapeutisches System zur Verabreichung von Buprenorphin |
DK2640389T3 (en) * | 2010-11-17 | 2015-03-09 | Hexal Ag | Transdermal therapeutic system comprising buprenorphine |
CN104114161A (zh) | 2011-12-12 | 2014-10-22 | Lts勒曼治疗系统股份公司 | 包含丁丙诺啡的经皮递送系统 |
WO2014051128A1 (ja) | 2012-09-28 | 2014-04-03 | 株式会社 ケイ・エム トランスダーム | 貼付剤 |
AU2013205080B2 (en) | 2012-12-12 | 2016-07-07 | Lts Lohmann Therapie-Systeme Ag | Transdermal Delivery System |
WO2014195352A1 (en) | 2013-06-04 | 2014-12-11 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system |
-
2014
- 2014-06-04 WO PCT/EP2014/061567 patent/WO2014195352A1/en active Application Filing
- 2014-06-04 HU HUE14171110A patent/HUE031662T2/en unknown
- 2014-06-04 AR ARP140102182A patent/AR096521A1/es unknown
- 2014-06-04 TN TN2015000493A patent/TN2015000493A1/en unknown
- 2014-06-04 ES ES14171110.1T patent/ES2599802T3/es active Active
- 2014-06-04 SI SI201430078A patent/SI2810646T1/sl unknown
- 2014-06-04 PE PE2015002556A patent/PE20160002A1/es not_active Application Discontinuation
- 2014-06-04 PL PL14171110T patent/PL2810646T3/pl unknown
- 2014-06-04 TW TW103119370A patent/TW201509416A/zh unknown
- 2014-06-04 DK DK14171110.1T patent/DK2810646T3/en active
- 2014-06-04 SG SG11201509218SA patent/SG11201509218SA/en unknown
- 2014-06-04 PT PT141711101T patent/PT2810646T/pt unknown
- 2014-06-04 DE DE112014002664.6T patent/DE112014002664T5/de not_active Withdrawn
- 2014-06-04 GB GB1522307.6A patent/GB2529789A/en not_active Withdrawn
- 2014-06-04 BR BR112015029920A patent/BR112015029920A2/pt not_active Application Discontinuation
- 2014-06-04 EP EP16173124.5A patent/EP3106153A1/en not_active Withdrawn
- 2014-06-04 CA CA2914425A patent/CA2914425C/en active Active
- 2014-06-04 EA EA201592246A patent/EA201592246A1/ru unknown
- 2014-06-04 US US14/772,474 patent/US20160008294A1/en not_active Abandoned
- 2014-06-04 MX MX2015016123A patent/MX362614B/es active IP Right Grant
- 2014-06-04 AU AU2014276910A patent/AU2014276910B2/en active Active
- 2014-06-04 LT LTEP14171110.1T patent/LT2810646T/lt unknown
- 2014-06-04 JP JP2016517285A patent/JP6559121B2/ja active Active
- 2014-06-04 CN CN201480032321.8A patent/CN105377245B/zh active Active
- 2014-06-04 AP AP2015008920A patent/AP2015008920A0/xx unknown
- 2014-06-04 KR KR1020157037128A patent/KR102302505B1/ko active IP Right Grant
- 2014-06-04 EP EP14171110.1A patent/EP2810646B1/en active Active
- 2014-06-04 MA MA38698A patent/MA38698B1/fr unknown
-
2015
- 2015-06-03 HK HK15105294.5A patent/HK1204766A1/zh unknown
- 2015-11-06 PH PH12015502550A patent/PH12015502550A1/en unknown
- 2015-11-17 CL CL2015003377A patent/CL2015003377A1/es unknown
- 2015-12-03 NI NI201500170A patent/NI201500170A/es unknown
- 2015-12-08 CR CR20150647A patent/CR20150647A/es unknown
- 2015-12-16 US US14/970,641 patent/US20160101100A1/en not_active Abandoned
- 2015-12-22 ZA ZA2015/09309A patent/ZA201509309B/en unknown
-
2016
- 2016-09-01 HK HK16110445.2A patent/HK1222135A1/zh unknown
- 2016-10-05 CY CY20161100988T patent/CY1118054T1/el unknown
-
2017
- 2017-01-24 US US15/414,138 patent/US20170128384A1/en not_active Abandoned
- 2017-11-22 US US15/820,978 patent/US20180092905A1/en not_active Abandoned
-
2020
- 2020-04-09 US US16/844,767 patent/US11529345B2/en active Active
- 2020-06-18 US US16/905,476 patent/US20200316055A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015502550A1 (en) | Transdermal delivery system | |
PH12014501231A1 (en) | Transdermal delivery system comprising buprenorphine | |
PH12015501169A1 (en) | Transdermal delivery system | |
JP2014218522A5 (es) | ||
MX2016008138A (es) | Sistema para el suministro transdermico de ingredientes activos. | |
MY163809A (en) | Transdermal drug delivery system containing donepezil | |
MX2022008277A (es) | Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas. | |
MX2016009493A (es) | Sistemas trasdermicos restrictivos de abuso y mal uso. | |
PH12015502280A1 (en) | Transdermal delivery system comprising donepezil or its salt | |
EP4321213A3 (en) | Oral octreotide administered in combination with other therapeutic agents | |
PH12016500666A1 (en) | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome | |
AR092820A1 (es) | Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit | |
WO2012111996A3 (ko) | 갈란타민 또는 그의 염을 함유하는 경피흡수제제 | |
MY184693A (en) | Bilayer hydrocolloid films containing therapeutic agents | |
WO2017053936A8 (en) | Cocrystals of naloxone and naltrexone | |
MX2015010967A (es) | Formulaciones transdermicas de laquinimod. | |
MX370898B (es) | Agente terapéutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor. | |
ECSP14008829A (es) | Sistema de administracion transdermica | |
Huilaja | Allergic contact dermatitis following transdermal administration: 3 case reports |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |